Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
56 Results for "
BxPC3
" in MedChemExpress (MCE) Product Catalog:
Products (56)
56 Results for "BxPC3" in MCE Product Catalog:
Cat. No.: HY-123009
CAS No.: 927823-01-6
Target:
HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase Apoptosis Carbonic Anhydrase VEGFR GLUT
Research Areas:
KCN1 is a p300/HIF-1α interaction inhibitor with a Kd value of 345 nM for p300-CH1. KCN1 binds to the CH1 domain of p300, blocks the assembly of the p300/HIF-1α complex, and disrupts the HIF-1α-p300/CBP interaction. KCN1 inhibits cancer cell growth, induces cancer cell cycle arrest and apoptosis. KCN1 inhibits β-galactosidase activity and downregulates the expression of VEGF, Glut1, CA9 and CAIX. KCN1 exerts anticancer activity in mouse tumor xenograft models. KCN1 can be used in research related to malignant glioma, pancreatic cancer and metastatic uveal melanoma [3].
Cat. No.: HY-170776
AXL/Angiokinase-IN-1 (compound 11b) is an AXL/triple angiokinase inhibitor, IC50=3.75 nM (AXL expression). AXL/Angiokinase-IN-1 inhibits epithelial-mesenchymal transition (EMT) in Bxpc-3, blocking lung cancer cell metastasis. AXL/Angiokinase-IN-1 also inhibits vascular and fibroblast functions, promoting apoptosis (apoptosis) in cancer cells and fibroblasts. AXL/Angiokinase-IN-1 features low toxicity and good metabolic stability .
Cat. No.: HY-178910
Target:
Research Areas:
Mcl-1-IN-20 (Compound 26d) is a Mcl-1 inhibitor with Kis of 0.59, 6.6 and 3.6 μM against Mcl-1, Bcl-xL and Bcl-2. Mcl-1-IN-20 exhibits significant anti-proliferative activity against pancreatic cancer cells and can induce apoptosis in BxPC-3 cells. Mcl-1-IN-20 can be used for the study of pancreatic cancer .
Cat. No.: HY-176284
Target:
Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) AMPK Keap1-Nrf2
Research Areas:
OXPHOS-IN-2 is an orally active OXPHOS inhibitor. OXPHOS-IN-2 exhibits potent inhibitory activity in PC9 (IC50 = 12.3 nM) and Bxpc-3 cells (IC50 = 250 nM in glucose medium, IC50 = 17.5 nM in galactose medium). OXPHOS-IN-2 decreases the NADH/NAD + ratio and reduces ATP levels. OXPHOS-IN-2 induces tumor cells apoptosis by activating reactive oxygen species (ROS) and downregulating the level of Nrf2. OXPHOS-IN-2 can be used for research on cancer such as non-small cell lung cancer and pancreatic cancer .
Cat. No.: HY-150696
CAS No.: 2676942-92-8
Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research .
Cat. No.: HY-174243
CAS No.: 2933935-13-6
KRASG12D-IN-5 (Compound 241) is an orally active KRAS(G12D) inhibitor with an IC50 of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC50s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer .
Cat. No.: HY-126493
Research Areas:
DM4-SPDP is a Drug-Linker Conjugates for ADC. DM4-SPDP consists of the ADC cytotoxin DM4 (HY-12454) and a linker SPDP (HY-100216). DM4-SPDP can be used for synthesis of ADCs .
Cat. No.: HY-177784
Research Areas:
iDeg-3 is a potent IDO1 molecular glue degrader. iDeg-3 binds to apo-IDO1 and alters its C-terminal conformation, promoting CRL2-KLHDC3 E3 ligase-mediated ubiquitination and degradation of IDO1. iDeg-3 is suitable for cancer-related research .
Cat. No.: HY-164895
CAS No.: 3080918-50-6
PIN1 degrader-1 is a covalent PIN1 degrader with an IC50 of 21.5 nM. PIN1 degrader-1 induces a decrease in the thermal stability of PIN1, and triggers PIN1 degradation in a concentration- and time-dependent manner across various cancer cells. PIN1 degrader-1 also reduces the viability of pancreatic cancer, breast cancer, prostate cancer and lung cancer cells. PIN1 degrader-1 can be used for research on pancreatic cancer, breast cancer, prostate cancer and non-small cell lung cancer .
Cat. No.: HY-161353
CAS No.: 3032969-28-8
Target:
Research Areas:
c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC50 = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .
Cat. No.: HY-N1410R
CAS No.: 42206-94-0
Target:
Cat. No.: HY-144311
CAS No.: 2749554-48-9
Research Areas:
OXPHOS-IN-1 (compound 2) is a oxidative phosphorylation (OXPHOS) inhibitor. OXPHOS-IN-1 inhibits the cells growth of MIA PaCa-2 and BxPC-3 cells with IC50s of 2.34 μM and 13.82 μM, respectively .
Cat. No.: HY-161614
CAS No.: 3025180-36-0
Target:
Research Areas:
Tubulin inhibitor 44 (Compound 26r) is an inhibitor for tubullin. Tubulin inhibitor 44 exhibits cytotoxicity in cancer cells NCI-H460, BxPC-3 and HT-29, with IC50s of 0.96, 0.66 and 0.61 nM, respectively .
Cat. No.: HY-120561
CAS No.: 1202401-59-9
Target:
Research Areas:
PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .
NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .
Cat. No.: HY-147725
CAS No.: 2411962-64-4
Target:
Research Areas:
Microtubule inhibitor 4 (compound 2) is a potent microtubule inhibitor. Microtubule inhibitor 4 shows cytotoxicity with IC50s of 4.0, 3.2, 2.1 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 4 shows the inhibition of tubulin polymerization .
Cat. No.: HY-147727
CAS No.: 2416338-64-0
Target:
Research Areas:
Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor. Microtubule inhibitor 6 shows cytotoxicity with IC50s of 14.0, 6.6, 7.0 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 6 efficiently inhibits microtubule polymerization .
Cat. No.: HY-163715
Antitumor agent-165 (Compound 10l) is a potent focal adhesion kinase (FAK) inhibitor. Antitumor agent-165 exhibits effective antiproliferative activity against CAPAN-1, PANC-1, PATU-T, SUIT-2, BxPC-3, PDAC-3 and PANC-1 GR with IC50s in the range of 1.04-3.44 μM .
Cat. No.: HY-173074
CAS No.: 3025180-14-4
Target:
Research Areas:
Microtubulin-IN-1 (Compound 8g) is the inhibitor for microtubulin that targets colchicine-binding site, disrupts the microtubulin integrity, and induces the upregulation of p53. Microtubulin-IN-1 exhibits antiproliferative activity in a variety of cancer cell lines (IC50 for NCI-H460, BxPC-3 and HT-29 is 2.4, 1.6 and 2.07 nM, respectively), arrests the cell cycle at G2/M phase, and induces apoptosis in NCI-H460 .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
